201 related articles for article (PubMed ID: 29318784)
1. Divalproex sodium modulates nuclear localization of ataxin-3 and prevents cellular toxicity caused by expanded ataxin-3.
Wang ZJ; Hanet A; Weishäupl D; Martins IM; Sowa AS; Riess O; Schmidt T
CNS Neurosci Ther; 2018 May; 24(5):404-411. PubMed ID: 29318784
[TBL] [Abstract][Full Text] [Related]
2. Polyglutamine-expanded ataxin-3 impairs long-term depression in Purkinje neurons of SCA3 transgenic mouse by inhibiting HAT and impairing histone acetylation.
Chou AH; Chen YL; Hu SH; Chang YM; Wang HL
Brain Res; 2014 Oct; 1583():220-9. PubMed ID: 25139423
[TBL] [Abstract][Full Text] [Related]
3. Divalproex sodium regulates ataxin-3 translocation likely by an importin α1-dependent pathway.
Wang Z; He F; Abeditashi M; Schmidt T
Neuroreport; 2019 Aug; 30(11):760-764. PubMed ID: 31107713
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3.
Chou AH; Chen SY; Yeh TH; Weng YH; Wang HL
Neurobiol Dis; 2011 Feb; 41(2):481-8. PubMed ID: 21047555
[TBL] [Abstract][Full Text] [Related]
5. Disulfiram facilitates ataxin-3 nuclear translocation and potentiates the cytotoxicity in a cell model of SCA3.
Wang Z
J Toxicol Sci; 2019; 44(8):535-542. PubMed ID: 31378764
[TBL] [Abstract][Full Text] [Related]
6. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse.
Chou AH; Chen YL; Chiu CC; Yuan SJ; Weng YH; Yeh TH; Lin YL; Fang JM; Wang HL
Neuropharmacology; 2015 Dec; 99():308-17. PubMed ID: 26254860
[TBL] [Abstract][Full Text] [Related]
7. Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4.
Yi J; Zhang L; Tang B; Han W; Zhou Y; Chen Z; Jia D; Jiang H
PLoS One; 2013; 8(1):e54792. PubMed ID: 23382971
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and aggregation of the polyglutamine disease protein, ataxin-3 is regulated by its binding to VCP/p97 in Drosophila melanogaster.
Ristic G; Sutton JR; Libohova K; Todi SV
Neurobiol Dis; 2018 Aug; 116():78-92. PubMed ID: 29704548
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid attenuates the suppression of acetyl histone H3 and CREB activity in an inducible cell model of Machado-Joseph disease.
Lin XP; Feng L; Xie CG; Chen DB; Pei Z; Liang XL; Xie QY; Li XH; Pan SY
Int J Dev Neurosci; 2014 Nov; 38():17-22. PubMed ID: 25068645
[TBL] [Abstract][Full Text] [Related]
10. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
11. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
12. Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3.
Sowa AS; Martin E; Martins IM; Schmidt J; Depping R; Weber JJ; Rother F; Hartmann E; Bader M; Riess O; Tricoire H; Schmidt T
Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2624-E2633. PubMed ID: 29476013
[TBL] [Abstract][Full Text] [Related]
13. Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo.
Watchon M; Luu L; Robinson KJ; Yuan KC; De Luca A; Suddull HJ; Tym MC; Guillemin GJ; Cole NJ; Nicholson GA; Chung RS; Lee A; Laird AS
Mol Brain; 2021 Aug; 14(1):128. PubMed ID: 34416891
[TBL] [Abstract][Full Text] [Related]
14. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
[TBL] [Abstract][Full Text] [Related]
15. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
[TBL] [Abstract][Full Text] [Related]
16. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds.
Tang B; Liu C; Shen L; Dai H; Pan Q; Jing L; Ouyang S; Xia J
Arch Neurol; 2000 Apr; 57(4):540-4. PubMed ID: 10768629
[TBL] [Abstract][Full Text] [Related]
17. Polyglutamine expansion of ataxin-3 alters its degree of ubiquitination and phosphorylation at specific sites.
Kristensen LV; Oppermann FS; Rauen MJ; Hartmann-Petersen R; Thirstrup K
Neurochem Int; 2017 May; 105():42-50. PubMed ID: 28065793
[TBL] [Abstract][Full Text] [Related]
18. CDK5 protects from caspase-induced Ataxin-3 cleavage and neurodegeneration.
Liman J; Deeg S; Voigt A; Voßfeldt H; Dohm CP; Karch A; Weishaupt J; Schulz JB; Bähr M; Kermer P
J Neurochem; 2014 Jun; 129(6):1013-23. PubMed ID: 24548080
[TBL] [Abstract][Full Text] [Related]
19. Treatment with sodium butyrate induces autophagy resulting in therapeutic benefits for spinocerebellar ataxia type 3.
Watchon M; Robinson KJ; Luu L; An Y; Yuan KC; Plenderleith SK; Cheng F; Don EK; Nicholson GA; Lee A; Laird AS
FASEB J; 2024 Jan; 38(2):e23429. PubMed ID: 38258931
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
